Found 44 All Conditions trials
Below is a list of actively recruiting clinical trials based on your search for "All Conditions"
Program with 1 clinical trials
Diabetes Type 1 - ACT18368, DRI17476, EFC18241
SAR439459 est un anticorps monoclonal humain anti-TGFβ. Cette étude clinique de phase 1 évalue l’innocuité, la tolérabilité et l’activité d’une dose unique de SAR439459 chez des participants adultes atteints d’OI. Les participants recevront une dose unique en intraveineuse de SAR439459 avec des évaluations de l’innocuité, de la pharmacocinétique (PK) et de …
This study is looking for individuals 18 to 65 years old with PKU. Sanofi believes that everyoneshould have the opportunity to take part in clinical trials. It is important to include people whohave been historically under-represented in clinical trials. Sanofi is committed to inclusivity inour studies.If you are interested in …
Objectif principal: Déterminer l'efficacité du SAR442168 par rapport au placebo pour retarder la progression de l'invalidité dans la sclérose en plaques progressive primaire (PPMS) Objectifs secondaires : Évaluer l'efficacité du SAR442168 par rapport au placebo sur les paramètres cliniques, les lésions d'imagerie par résonance magnétique (IRM), les performances cognitives, la …
Objectifs principaux : Cohorte A : Évaluer l’efficacité du BIVV020 dans la prévention du RMA Cohorte B : Évaluer l’efficacité du BIVV020 dans le traitement du RMA actif Objectifs secondaires : Évaluer l’efficacité globale du BIVV020 dans la prévention ou le traitement du RMA Caractériser l’innocuité et la tolérabilité du BIVV020 chez les participants ayant reçu …
This is a single group, Phase 2, long-term extension study for treatment. The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated adult participants with moderate to severe AD who have previously been enrolled in an amlitelimab clinical trial. Visits during the on-treatment period …
This is Phase 1/Phase 2, open label, multiple cohort, first-in-human study to evaluate safety, PK, PDy and efficacy of SAR444200 as a monotherapy or in combination with other anti-cancer agents for participants aged at least 18 years with previously treated metastatic malignancies.
This is a single group, treatment, Phase 3, open-label, single-arm study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy (IST) without firstline therapeutic plasma exchange (TPE) with primary endpoint of remission in male and female participants aged 18 to 80 years with immune-mediated thrombotic thrombocytopenic purpura (iTTP). …
